In recent years, there has been interest in the study of alterations of the immune system of breast carcinoma patients undergoing primary chemotherapy. Changes in the phenotype, function of peripheral blood lymphocytes as well as alterations in the release of pro-inflammatory cytokines accompanying the administration of primary chemotherapy have been described. We have investigated urinary neopterin and peripheral blood leukocyte phenotype in 44 breast carcinoma patients treated with the combination of doxorubicin and paclitaxel. Compared to controls, patients with breast carcinoma had significantly lower relative number of CD3 lymphocytes. When ratio of peripheral blood leukocyte counts at visit 2/visit 1 was calculated, patients without lymph node involvement at surgery also had significantly increased ratio of relative lymphocyte numbers, relative and absolute CD14 + DR + monocyte numbers. In conclusion, systemic immune activation in breast carcinoma patients treated with doxorubicin and paclitaxel is associated with significant changes of peripheral blood leukocyte phenotype, including an increase of relative and absolute numbers of CD3 + CD4 + lymphocytes.
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Introduction
Breast carcinoma is the most frequent malignancy in women (1) . Progress, that has been accomplished in the therapy of breast carcinoma in the last decades, lead to improved survival. In addition to early diagnosis improvement of prognosis of breast carcinoma patients is also the result of systemic therapy, including cytotoxic chemotherapy (2) .
Primary systemic (neoadjuvant) therapy is the treatment of choice in locally advanced breast carcinoma, and this approach is being increasingly used also in patients with operable tumors (3, 4) . Although both hormonal and cytotoxic drugs may be used in primary systemic therapy, chemotherapy with cytotoxic agents is the preferred modality in most cases as the activity of hormonal therapy is restricted to patients with tumors expressing hormone receptors, and response onset is more rapid and response more pronounced with administration of cytotoxic agents. Currently, most regimens of primary systemic chemotherapy comprise an anthracycline-based combination with or without taxanes. The combination of doxorubicin and paclitaxel represents an effective regimen of cytotoxic chemotherapy both in the palliative as well as in neoadjuvant setting (5, 6) .
In recent years, there has been considerable interest in the study of alterations of the immune system of breast carcinoma patients undergoing primary chemotherapy. Changes in the phenotype, and function of peripheral blood lymphocytes as well as alterations in the release of pro-inflammatory cytokines accompanying the administration of primary chemotherapy have been described (7) (8) (9) . In a preliminary report in 11 patients, we have described an increase of CD3+,  CD3   +   CD4   +   , CD3   +   CD8   +   and CD8   +   CD28   + T-lymphocytes after treatment with the combination of doxorubicin and paclitaxel (10) . We present here results of an expanded cohort of patients with breast carcinoma receiving this regimen and a longer observation period.
Patients and Methods

Patients
In 44 patients, all females, aged 58 ± 10 (range 38 -76) years, with histologically confirmed breast carcinoma, peripheral blood leukocyte phenotype was determined before the neoadjuvant chemotherapy and after 1-3 chemotherapy cycles. In 30 patients one or two additional measurements before the subsequent chemotherapy cycles were performed. Eleven healthy females, aged 47 ± 13 (range 28 -75) years served as controls. The patients have been treated with 3 -6 cycles of the combination of doxorubicin (50 mg/m 2 for 1 hour) and paclitaxel (175 mg/m 2 3-hour infusion) every 3 weeks. Clemastine (2 mg), ranitidine (50 mg), granisetrone (3 mg) and dexamethasone (16 mg) were administered as premedication before each cycle. Pathological response was evaluated based on criteria described by Chevallier et al. (11) . Samples of urine and peripheral blood were obtained before the administration of chemotherapy in the morning hours. Peripheral blood cell count was performed immediately, and morning urine specimens were collected and stored at -20 ο C until analysis (that was performed within 3 months of sample collection). Preliminary results of peripheral blood leukocyte phenotype changes after a single cycle of chemotherapy in the cohort of first 11 patients included in the present study as well as analyses of correlations of neopterin with hemoglobin and peripheral blood platelet counts in some patients included in the present analysis have been published (10, 12) .
Determination of urinary neopterin
Urinary neopterin was measured by high-performance liquid chromatography (13) . Briefly, after centrifugation (5 min, 1300 x g) and diluting 100 µl of urine specimens with 1.0 ml of mobile phase containing 2 g of disodium-EDTA per liter, a 20 µl sample was injected onto a column. Neopterin was determined by reversed-phase high performance liquid chromatography system LC1084A (Hewlett-Packard, Palo Alto, USA) with HP 79850 A integrator (Hewlett-Packard). Potassium phosphate buffer (15 mmol/l, pH 6.4) at flow rate of 0.8 ml/min was used as mobile phase. Neopterin was identified by its native fluorescence (353 nm excitation, 438 nm emission) by MPF-3 detector (Perkin-Elmer, Norwalk, USA) and quantified by external standard method. Creatinine was determined by Jaffé reaction after dilution of sample 1:50 (v/v) on a Hitachi 716 analyzer (Tokyo, Japan) with commercial kit (Boehringer, Mannheim, Germany) according to the manufacturer's instructions, and neopterin concentrations were expressed as neopterin/creatinine ratio (µmol/mol creatinine) as described earlier. Peripheral blood cell count was performed as described (14) . Leukocytes were detected by flow cytometry using a Sysmex XE-2100 blood analyzer (Sysmex, Kobe, Japan) and differential blood cell count was performed. leukocytes were analyzed by two-color flow cytometry as described earlier (15) . Briefly, 25 µl of heparinized peripheral blood were mixed with 10 µl of respective monoclonal antibody solution and incubated for 20 minutes at room temperature. The fluorescein isothiocyanate conjugated (FITC) and phycoerythrin conjugated (PE) monoclonal antibodies or combinations of monoclonal antibodies were used to define respective leukocyte populations. These monoclonal antibodies conjugates were obtained from Immunotech (Marseille, France) and Becton Dickinson (San Jose, CA, USA). After the incubation, 135 µl of lysing solution (OptiLyse C, Immunotech) was added, and the mixture was incubated for 10 minutes. The suspension was then washed in 1.5 ml saline and centrifuged for 10 minutes at 125 g. Subsequently, the supernatant was discarded, and the sediment was resuspended in 250 µl of saline. Flow cytometric analysis was performed using EPICS XL flow cytometer (Coulter, Miami, FLA, USA), and the analysis was based on 5 -10 x 10 3 gated events. Anti-CD45-FITC/anti-CD14-PE (Leuco-GATE, Becton Dickinson) was used to establish and verify the light scatter gate for lymphocytes. The purity of lymphocytes in the light scatter gate was consistently above 90 %. Monocyte gating was based on the on CD14 staining. Simultaneously, peripheral blood cell count and white blood cell differential count were performed, and absolute numbers of respective leukocyte population were calculated. Results were expressed as absolute numbers of cells per µl.
Analysis of peripheral blood leukocyte phenotype
Statistical analysis
Urinary neopterin concentrations and peripheral blood leukocyte phenotype of patients, controls and different groups of patients based on pathological response were compared by Mann-Whitney U test, urinary neopterin and peripheral blood leukocyte phenotype before and during the treatment was compared by Wilcoxon signed rank test, and correlations between urinary neopterin and hematological parameters were investigated with Spearman's rank correlation. The decision on statistical significance was based on p = 0.05 level. The analyses were performed using NCSS 2001 software (Number Cruncher Statistical Systems, Kaysville, Utah, USA).
Results
Compared to controls, patients with breast carcinoma had significantly lower relative number of CD3 (Table 1) . Urinary neopterin and peripheral blood leukocyte phenotype was followed in breast carcinoma patients treated by primary chemotherapy with doxorubicin and paclitaxel before the start of the treatment (visit 1) and on 3 subsequent visits in approximately monthly intervals (Table 2 ). Compared to pretreatment values, urinary neopterin was significantly increased throughout the course of therapy ( Figure 1 ). Peripheral blood leukocyte count was increased on visits 2 and 3, but not on visit 4. The relative number of lymphocytes remained unchanged, but the absolute number of lymphocytes was significantly increased on visits 2 and 3. Table 2 . Urinary neopterin and peripheral blood leukocyte phenotype during primary chemotherapy with doxorubicin and paclitaxel.Shown are the means (± standard deviation; range) of the respective parameters. *p < 0.05; **p < 0.01; and ***p < 0.001. surgery was performed (5 patients) or because radiotherapy has been administered before mastectomy (2 patients). The reason for not performing surgery was either patient refusal (2 patients), distant metastases detected at diagnosis or during neoadjuvant therapy (2 patients) and technical inoperability (1 patients). These patients were treated with radical radiotherapy. Among the remaining 37 patients, pathological complete response of the primary tumor was observed in 7 cases. In 7 patients with pathological complete response of the primary tumor, relative numbers of lymphocytes were significantly (p < 0.05) lower at baseline (23 ± 7 % vs. 29 ± 8 %) and at visit 2 (20 ± 3 % vs. 31 ± 10 %). Only one patient with pathological complete response had tumor in the lymph nodes. /l vs. 8.9 ± 2.9 x 10 9 /l; p < 0.05). When ratio of peripheral blood leukocyte counts at visit 2/visit 1 was calculated, patients without lymph node involvement at surgery also had significantly increased ratios of relative lymphocyte numbers (1.35 ± 0.49 vs. 0.93 ± 0.36; p < 0.01), relative (1.55 ± 2.16 vs. 0.80 ± 0.51; p < 0.05) and absolute (2.14 ± 3.14 vs. 0.95 ± 0.78; p < 0.05) CD14 + DR + monocyte numbers.
Discussion
In the present study only subtle changes in the peripheral blood phenotype indicative of immune activation, e.g. an increase in the numbers of NK cells, CD3 lymphocytes, no changes were observed in the expression of lymphocyte activation markers. An obvious limitation of the present study is the design in which the samples were taken in 3-week intervals immediately before the administration of therapy, and no conclusions can be made about the peripheral blood leukocyte phenotype at other time points during each chemotherapy cycle.
Immunomodulatory effects of paclitaxel that included stimulation of the production of cytokines, e.g. interleukin-1, tumor necrosis factor-α or interleukin-12, have been described in experimental studies (16) (17) (18) . These immunomodulatory effects could be responsible for the marked increase in lymphocytes and monocytes observed during the therapy. The increase of CD4 + T-lymphocytes observed in the present study is in contrast to other reports of peripheral blood lymphocytes phenotype in breast cancer patients treated with primary chemotherapy. Sewell et al. (19) observed a marked decrease of CD4 + T-lymphocytes in patients with advanced breast carcinoma treated with the combination of cyclophosphamide, methotrexate and 5-fluorouracil. A decrease of CD4 + T-lymphocytes was also described by Murta et al. (7) in advanced breast carcinoma patients treated with the combination of 5-fluorouracil, epirubicin and cyclophosphamide. On the other hand, marked decrease of B-lymphocytes has been evident in the present study as well as in both reports mentioned above. It is possible that different chemotherapy regimens have differential effects on the lymphocyte subpopulations. The administration of alkylating agents, e.g. cyclophosphamide, may lead to lymphocyte depletion (20) , but in patients treated with taxane-based therapy, the immunostimulatory activity could prevail. The increase of peripheral blood lymphocytes may augment the immune response against the tumor. An increase of CD14 + CD16 + monocytes in cancer patients is well known (21) , and the present data demonstrate that absolute numbers of this monocyte subpopulation increases further during primary chemotherapy with doxorubicin and paclitaxel.
The changes in peripheral blood phenotype observed in the present study have been accompanied by an increase in urinary neopterin, an indicator of systemic immune activation. Neopterin is an unconjugated pteridine synthesized from guanosine triphosphate (GTP). GTP is converted to 7,8-dihydroneopterin by the enzyme guanosine triphosphate cyclohydrolase I (GTP cyclohydrolase I) in the first step of the pathway leading to the formation of tetrahydrobiopterin (22) . The activity of GTP cyclohydrolase I, the rate limiting enzyme in this pathway, is induced by interferon-(IFN-γ) (23) produced by T-lymphocytes and NK cells. Human macrophages possess significant GTP cyclohydrolase I activity when stimulated by IFN-γ, while the activity of other enzymes of this pathway is low (24) , leading to the accumulation of 7,8-dihydroneopterin which undergoes autooxidation to neopterin. The ratio of 7,8-dihydroneopterin to neopterin is constant (25) , and therefore neopterin concentrations are used to assess in vivo macrophage activation and, because neopterin production is the result of activation by IFN-γ, systemic immune activation. An increase in serum or urinary neopterin concentrations in cancer patients has been amply documented (26, 27) , but neopterin concentrations are increased only in a minority of patients with breast carcinoma (28) . The observation of increased urinary neopterin after primary chemotherapy is in agreement with the reports of increased serum concentrations of pro-inflammatory cytokines after the administration of taxanes (also in breast carcinoma in neoadjuvant setting) (8, 9) . Increased serum levels of pro-inflammatory cytokines have been associated with flu-like symptoms and fatigue accompanying paclitaxel administration (8) . Higher serum concentrations of pro-inflammatory cytokines and neopterin have also been reported in breast cancer survivors suffering from fatigue (29) . Based on these data it appears likely that systemic inflammatory and immune activation that accompanies taxane-based chemotherapy may be responsible for some of the side effects, notably flu-like syndrome and fatigue. It has been demonstrated that systemic inflammatory reaction is responsible for flu-like syndrome accompanying administration of other cytotoxic drugs, e.g. gemcitabine (30) (15) . It has been shown in patients with HIV infection that apoptosis occurs mostly in the noninfected (bystander) cells (32) , and that apoptosis correlates positively with activation of lymphoid tissues (33) . Similarly to HIV infection, systemic immune activation in cancer patients seems to be associated with the loss of T-helper lymphocytes in peripheral blood, and mechanisms similar to patients with AIDS, including activation-induced apoptosis, or expression of Fas ligand by the tumor cells (Fas counterattack) may be responsible for this phenomenon in cancer patients (34) . In addition to the negative correlation with relative and absolute numbers of CD3 The present results suggest that changes in peripheral blood leukocyte phenotype could reflect an involvement of immune system in antitumor activity of the primary chemotherapy in breast carcinoma. The most important measure of effectiveness of primary chemotherapy is the proportion of patients with complete disappearance of the tumor (pathological complete response). Although pathological complete response is usually observed in a minority of patients, it is the strongest indicator of excellent long-term prognosis (35) (36) (37) (38) . Another related prognostic indicator in patients after primary chemotherapy is the absence of lymph node involvement in operative specimen (39, 40) . In the present study, patients with pathological complete response had significantly lower baseline absolute lymphocyte numbers. In addition, patients without lymph node involvement detected in surgical specimen had significantly lower total numbers of lymphocytes, CD3 lymphocytes, but more pronounced rise of T-lymphocytes during the therapy. Although the present data are retrospective and therefore only hypothesis-generating, they seem to indicate that the rise in peripheral blood T-lymphocytes could be associated with tumor clearance during neoadjuvant chemotherapy. An increase in tumor infiltrating lymphocytes has been described after neoadjuvant administration of paclitaxel (41) , and tumor infiltration by cytotoxic lymphocytes could represent a mechanism of tumor elimination during neoadjuvant chemotherapy (42) .
In conclusion, urinary neopterin and the numbers of CD3 + lymphocytes decreased during the therapy with a combination of doxorubicin and paclitaxel. A significant correlation was observed between urinary neopterin and peripheral blood leukocyte phenotype before and during the course of therapy.
